Hemopexin

01/26/2022 - "Hemopexin had a half-life in wild-type mice, rats, and non-human primates of 80-102 h, whereas a reduced half-life of hemopexin in Townes SCD mice was observed due to ongoing hemolysis. "
01/01/2021 - "RBCs from SCD mice had significant levels of carbonylation (which predisposes RBCs to hemolysis) 6 h post-Cl2 exposure which were absent in RBCs of mice treated with hemopexin. "
01/01/2020 - "Blood was taken at different timepoints to determine the pharmacokinetic of injected hemopexin in presence and absence of hemolysis. "
01/01/2020 - "Therefore, we hypothesized that injection of hemopexin will prevent hemolysis-induced complement activation. "
01/01/2020 - "Hemopexin as an Inhibitor of Hemolysis-Induced Complement Activation."

08/01/2003 - "Further study of hemopexin may provide clues for new therapeutic strategies aimed at interfering with PMN adhesion to control inflammation and tissue injury."
07/10/2000 - "Respective roles of inflammation and axonal breakdown in the regulation of peripheral nerve hemopexin: an analysis in rats and in C57BL/Wlds mice."
12/01/1992 - "Hemopexin was purified to apparent homogeneity from pools of serum samples derived from rats with yeast induced inflammation, a monospecific polyclonal antibody was prepared and was used for immunoblot analysis. "
09/01/2016 - "Hepatic Overexpression of Hemopexin Inhibits Inflammation and Vascular Stasis in Murine Models of Sickle Cell Disease."
04/15/2015 - "Hemopexin in severe inflammation and infection: mouse models and human diseases."

06/15/2021 - "In summary, the current research indicates that hemopexin is likely protective against these symptoms and that rectifying depleted hemopexin in patients with sickle cell disease could improve or prevent the symptoms. "
01/26/2022 - "Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence."
11/01/2021 - "Hemopexin dosing improves cardiopulmonary dysfunction in murine sickle cell disease."
06/15/2021 - "Critical Role of Hemopexin Mediated Cytoprotection in the Pathophysiology of Sickle Cell Disease."
04/01/2011 - "Hemopexin deficiency, which is often associated with sickle cell disease, may worsen outcome after ICH."

01/17/2022 - "Hemopexin and Cancer."
09/23/2011 - "Thus, targeting the MMP-14 hemopexin domain represents a novel approach to inhibit MMP-14-mediated cancer dissemination."
01/01/1984 - "Finally, a positive statistical correlation between solid type tumor weight and hemopexin concentration in the mouse was observed."
12/01/1977 - "Hemopexin metabolism in mice with transplantable tumors."
08/01/2007 - "Here, for the first time, we show the efficacy of therapeutic ultrasound to deliver genes encoding for hemopexin-like domain fragment (PEX), an inhibitor of angiogenesis, to prostate tumors in vivo. "

08/01/2005 - "Previous studies into the relevance of a putative circulating factor in the pathogenesis of minimal change nephrotic syndrome have opened the possibility that plasma hemopexin might be an important effector molecule in this disorder. "
10/01/2005 - "Altered activity of plasma hemopexin in patients with minimal change disease in relapse."
04/01/2000 - "The human plasma constituent hemopexin (Hx), following incubation with renal tissue, is able to induce glomerular alterations in vitro that are similar to those seen in minimal change disease (MCD). "
11/01/2008 - "When infused into rats, hemopexin induces reversible proteinuria, and activated hemopexin is increased in children with minimal change nephrotic syndrome. "
08/01/2005 - "It is concluded that the hemopexin molecule as such can potentially act as a toxic protease, leading in the rat to proteinuria and glomerular alterations characteristic for minimal change nephrotic syndrome."